1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Neurological Biomarkers Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Neurological Biomarkers Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 Rising incidences of neurological diseases
- 5.1.3 Rapid Developments in healthcare
5.2 Market Opportunities
- 5.2.1
- 5.2.2 Development of novel biomarkers
- 5.2.3 Integration of drug development and biomarkers
- 5.2.4 Focus on early detection and prevention
5.3 Future Trends
- 5.3.1
- 5.3.2 Advancement in biomarker discovery
- 5.3.3 increased focus on personalized medicines
5.4 Impact of Drivers and Restraints
6. Europe Neurological Biomarkers Market Regional Analysis
6.1 Europe Neurological Biomarkers Market Overview
6.2 Europe Neurological Biomarkers Market Revenue 2017-2027 (US$ Million)
6.3 Europe Neurological Biomarkers Market Forecast Analysis
7. Europe Neurological Biomarkers Market Analysis – by Product
7.1 Proteomics Biomarker
- 7.1.1 Overview
- 7.1.2 Proteomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Genomics Biomarker
- 7.2.1 Overview
- 7.2.2 Genomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Metabolomics Biomarker
- 7.3.1 Overview
- 7.3.2 Metabolomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Imaging Biomarker
- 7.4.1 Overview
- 7.4.2 Imaging Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Neurological Biomarkers Market Analysis – by Application
8.1 Alzheimer's Disease
- 8.1.1 Overview
- 8.1.2 Alzheimer's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Parkinson's Disease
- 8.2.1 Overview
- 8.2.2 Parkinson's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Schizophrenia
- 8.3.1 Overview
- 8.3.2 Schizophrenia: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Huntington's Disease
- 8.4.1 Overview
- 8.4.2 Huntington's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Spinal Muscular Atrophy
- 8.5.1 Overview
- 8.5.2 Spinal Muscular Atrophy: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
9. Europe Neurological Biomarkers Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Spinal Muscular Atrophy: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Clinical Diagnostics
- 9.2.1 Overview
- 9.2.2 Spinal Muscular Atrophy: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Research Organizations
- 9.3.1 Overview
- 9.3.2 Spinal Muscular Atrophy: Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
10. Europe Neurological Biomarkers Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Neurological Biomarkers Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Europe Neurological Biomarkers Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 UK: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.1.2 UK: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.1.3 UK: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.1.1.2 Germany:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Germany: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.2.2 Germany: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.2.3 Germany: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.1.1.3 France:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 France: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.3.2 France: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.3.3 France: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.1.1.4 Russia:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Russia: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.4.2 Russia: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.4.3 Russia: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.1.1.5 Italy:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.5.1 Italy: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.5.2 Italy: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.5.3 Italy: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.1.1.6 Rest of Europe:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.1.1.6.2 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.1.1.6.3 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Neurological Biomarkers Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Thermo Fisher Scientific, Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Myriad Genetics
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 QIAGEN
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Abbott
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck KGaA
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Europe Neurological Biomarkers Market
